Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santaris makes executive appointments

This article was originally published in Scrip

Executive Summary

Denmark-based Santaris Pharma has expanded its executive team, appointing Dr Mark Wedel vice-president and chief medical officer and Stuart Mackey vice-president of strategy and chief business officer. Dr Wedel, who will be responsible for global clinical development programmes and therapeutic portfolio management, joins from Isis Pharmaceuticals, where he was senior vice-president of drug development and chief medical officer. Mr Mackey spent the last 10 years at Amgen, where he most recently served as managing director of Amgen Ventures. They will be responsible for driving global business development for Santaris's proprietary RNA-targeted Locked Nucleic Acid drug platform. Both executives will be located at the company's recently established US subsidiary in San Diego, California.

You may also be interested in...



BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science

A former senior leader in Johnson & Johnson’s medical devices business will take over the reins of the Biotechnology Innovation Organization from Jim Greenwood in June. McMurry-Heath – who also spent four years at the US FDA's device center as associate director of science – brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.

Virtual Advisory Committees Pose Technical And Practical Challenges For US FDA, Sponsors

Recent panel review of biologics center's intramural research programs had its share of technical glitches and involved agency speakers blindly presenting to committee members they could not see; the experience suggests the difficulties an industry sponsor with an application hanging in the balance may face if a virtual advisory committee were to be held.

For COVID-Impacted Studies, FDA Loosens Video Conferencing Rules

Use of alternative labs or imaging centers depends upon type of assessment and reason it is being performed, the US agency's revised guidance states; missed milestones for postmarketing studies required under accelerated approval will need to be justified.

Topics

Related Companies

UsernamePublicRestriction

Register

CO236048

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel